Login to Your Account



Uniqure's Parkinson's Gene Therapy Moves into Clinic

By Nuala Moran
Staff Writer

Wednesday, July 31, 2013
LONDON – The first patient has been treated in a Phase I trial of Uniqure BV's gene therapy for Parkinson's disease, with the company's CEO Jörn Aldag personally assisting in the surgery, in which the gene for glial cell line-derived neurotrophic factor (GDNF) was administered directly into the brain.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription